Evidence map›Paper›PMID 37483612›Full record

ArticleFrontiers in immunology2023

Assessment of BoHV-4-based vector vaccine intranasally administered in a hamster challenge model of lung disease.

Seok-Chan Park, Laura Conti, Valentina Franceschi, Byungkwan Oh, Myeon-Sik Yang, Gaeul Ham, Antonino Di Lorenzo, Elisabetta Bolli, Federica Cavallo, Bumseok Kim and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Seok-Chan ParkBiosafety Research Institute and Laboratory of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, Republic of Korea.
Laura ContiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Valentina FranceschiDepartment of Medical Veterinary Sciences, University of Parma, Parma, Italy.
Byungkwan OhBiosafety Research Institute and Laboratory of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, Republic of Korea.
Myeon-Sik YangBiosafety Research Institute and Laboratory of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, Republic of Korea.
Gaeul HamBiosafety Research Institute and Laboratory of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, Republic of Korea.
Antonino Di LorenzoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Elisabetta BolliDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Federica CavalloDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Bumseok KimBiosafety Research Institute and Laboratory of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, Republic of Korea.
Gaetano DonofrioDepartment of Medical Veterinary Sciences, University of Parma, Parma, Italy.
Jeonbuk National University · KRUniversity of Turin · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Bovine herpesvirus 4 (BoHV-4) is a bovine Methods: In the present study, recombinant BoHV-4, BoHV-4-A-S-ΔRS-HA-ΔTK, was constructed to deliver an expression cassette for the SARS-CoV-2 spike glycoprotein, and its immunogenicity, as well as its capability to transduce cells of the respiratory tract, were tested in mice. The well-established COVID-19/Syrian hamster model was adopted to test the efficacy of intranasally administered BoHV-4-A-S-ΔRS-HA-ΔTK in protecting against a SARS-CoV-2 challenge. Results: The intranasal administration of BoHV-4-A-S-ΔRS-HA-ΔTK elicited protection against SARS-CoV-2, with improved clinical signs, including significant reductions in body weight loss, significant reductions in viral load in the trachea and lungs, and significant reductions in histopathologic lung lesions compared to BoHV-4-A-S-ΔRS-HA-ΔTK administered intramuscularly. Discussion: These results suggested that intranasal immunization with BoHV-4-BV induced protective immunity and that BoHV-4-BV could be a potential vaccine platform for the protection of other animal species against respiratory diseases.

Indexed as

COVID-19Herpesvirus 4, BovineViral VaccinesAdministration, IntranasalAnimalsCricetinaeMiceSARS-CoV-2Viral VaccinesBoHV-4-based vectorimmune responseintranasal vaccinationlung diseasevaccine

Identifiers

PMID37483612
PMCPMC10358724
OpenAlexW4383341396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.